The Strüngmann Group
Thomas and Andreas Strüngmann are among the most outstanding entrepreneurs in the pharmaceutical industry. In the mid-1980s, they founded HEXAL AG, the largest German generic drug company, which they subsequently sold in 2005 to Novartis for USD 7.5 billion, along with their shares in U.S.-based Eon Labs. Since then, Thomas and Andreas Strüngmann have been engaged in considerable investments in the German biotechnology innovation sector as well as the generics industry.
About The Strüngmann Group
Thomas and Andreas Strüngmann are among the most outstanding entrepreneurs in the pharmaceutical industry. In the mid-1980s, they founded HEXAL AG, the largest German generic drug company, which they subsequently sold in 2005 to Novartis for USD 7.5 billion, along with their shares in U.S.-based Eon Labs. Since then, Thomas and Andreas Strüngmann have been engaged in considerable investments in the German biotechnology innovation sector as well as the generics industry.